The White House is expected to nominate Dr. Scott Gottlieb, a physician and conservative health policy expert, to lead the US Food and Drug Administration, sources familiar with the matter said.
If confirmed by the Senate, Gottlieb would be in charge of implementing President Donald Trump’s plan to dramatically cut regulations governing food, drugs, cosmetics, dietary supplements and tobacco.
Gottlieb, 44, is a resident fellow at the conservative American Enterprise Institute think tank and a partner at a large venture capital fund. He is a former FDA deputy commissioner who has frequently advocated a loosening of requirements needed for approval of new medical products.
Gottlieb is well-known on Capitol Hill, where he has testified multiple times on hot-button health issues, including complex drug pricing matters, and is viewed favorably by the pharmaceuticals industry.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Le Monde, Le Figaro, and Le Parisien Sue X for Allegedly Using Content Without Payment
Nov 12, 2024 by
CPI
Musk’s Influence on AI Safety Could Lead to Stricter Standards in New Trump Era
Nov 12, 2024 by
CPI
DOJ and States File Suit to Block UnitedHealth’s $3.3B Acquisition of Amedisys
Nov 12, 2024 by
CPI
US Supreme Court Denies DOJ’s Request to Review Bid-Rigging Case
Nov 12, 2024 by
CPI
South Korea Proposes Legislation to Support Chipmakers
Nov 12, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI